近日，由浙江大学医学院第二附属医院吴明、沈虹教授开展的一项单臂、II期临床试验结果，正式发表于国际综合性期刊自然子刊Nature Communications。该研究结果为斯鲁利单抗联合化疗新辅助治疗可切除的局部进展期食管鳞癌（ESCC）提供了临床证据。该新辅助治疗方案表现出较高的病理完全缓解率（pCR）、疾病控制率和可控的安全性。

COVID-19 tests are in greater demand than ever, and new data about the Omicron variant can make picking and using different types of tests confusing. Molecular tests for COVID-19, like the "RT-PCR" ...

Ducharme is a contributor to TIME. Ducharme is a contributor to TIME. If you had COVID-19 symptoms in 2020, you probably would have masked up and braved a visit to a laboratory, doctor’s office, or ...

Social media users have been sharing screenshots purporting that the World Health Organization (WHO) released guidance to laboratories and incorrectly saying this was to reduce the positive test ...

The potential of the pCR to expedite the testing of cancer therapies is undeniable. The effect size on the pCR can be quite large, which substantially reduces the required sample size. The event is ...